Drug
Zasocitinib
Zasocitinib: highest development phase Phase 3, developed by Takeda. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Zasocitinib NCT07752108 | Phase 3 | Palmoplantar Psoriasis |
| Zasocitinib (Dose A) NCT07244263 | Phase 2 | Hidradenitis Suppurativa |
| Zasocitinib NCT07108283 | Phase 2 | Nonsegmental Vitiligo |
Latest
No recent events.
Follow Zasocitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.